Shubha Bhat
Overview
Explore the profile of Shubha Bhat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
294
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bhat S, Choi D
Ann Pharmacother
. 2025 Jan;
10600280241305441.
PMID: 39800899
Objective: To summarize the evidence and pharmacologic profile of guselkumab for moderate to severe ulcerative colitis (UC). Data Sources: A PubMed search from inception to end of October 2024 using...
2.
Donnelly R, Cavallari L, McCune J, Trofe-Clark J, Formea C, Hoffecker G, et al.
J Am Coll Clin Pharm
. 2024 Nov;
7(6):581-588.
PMID: 39582510
Pharmacogenomics is a growing area of medicine, and pharmacists across clinical practice settings have the opportunity to individualize medication selection and dosing using genetic data. However, many practicing pharmacists may...
3.
Jordan A, Bhat S, Ali T, Brunskill S, Clusen N, Maltz R, et al.
Inflamm Bowel Dis
. 2024 Oct;
PMID: 39377748
Background: A prior survey disseminated in 2017 identified that healthcare access barriers exist and significantly affect patients with inflammatory bowel disease (IBD). We sought to identify, through an updated survey,...
4.
Bhat S, Kane S
Gastroenterol Hepatol (N Y)
. 2024 Aug;
20(7):376-382.
PMID: 39206027
Annual out-of-pocket expenditures for patients with inflammatory bowel disease (IBD) are estimated to be as high as $41,000, with medications, such as biologics, being one of the main cost contributors....
5.
Bhat S, Varambally S, Jagannathan A, Phillip M
Asian J Psychiatr
. 2024 Jul;
99:104156.
PMID: 39079446
Background: The standard treatments for Obsessive Compulsive Disorder (OCD) have been pharmacological and psychotherapeutic, with preliminary evidence for yoga as an intervention. Aim: To test the short-term effects of a...
6.
Shetty K, Kishan Prasad H, Kotian S, Joshi D, Mathias L, Bhat S
J Cancer Res Ther
. 2024 Jul;
20(3):1100-1102.
PMID: 39023626
Leiomyosarcoma (LMS) represents one of the most common soft tissue sarcomas, involving various anatomical sites like the retroperitoneum, genitourinary tract, and extremities. LMS of the bone is extremely rare, with...
7.
Syed H, Nadeem A, Gardinier D, Weekley K, Ribakow D, Lupe S, et al.
Curr Gastroenterol Rep
. 2024 Feb;
26(5):125-136.
PMID: 38421577
Purpose Of Review: The management of patients with Crohn's disease (CD) undergoing surgery is complex and optimization of modifiable factors perioperatively can improve outcomes. This review focuses on the perioperative...
8.
Choi D, Sheridan H, Bhat S
Ann Pharmacother
. 2024 Feb;
58(11):1134-1139.
PMID: 38344998
Objective: To review the pharmacologic and clinical profile of mirikizumab in the treatment of moderate to severe ulcerative colitis (UC). Data Sources: A PubMed search was performed from inception to...
9.
Choi D, Becker M, Ivanov M, Bhat S
Ann Pharmacother
. 2024 Jan;
58(10):1054-1063.
PMID: 38258760
Objective: To review the pharmacologic and clinical profile of etrasimod in the treatment of ulcerative colitis (UC). Data Sources: A PubMed search was conducted from inception to November 2023 using...
10.
Angyal A, Bhat S
Curr Gastroenterol Rep
. 2024 Jan;
26(3):77-85.
PMID: 38243154
Purpose Of Review: Biosimilars were introduced to decrease biologic-related expenditures, but their uptake in inflammatory bowel disease (IBD) remains suboptimal. Herein, we review biosimilar concepts, current products available for IBD...